Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 4/20 | 0.38 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.37 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.34 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30679730 | 1.00 | PTGS1 (0.42) | PTGS1GSTK1TGFBR1OPRD1OPRM1 | |
| SCHEMBL265263 | 1.00 | PTGS1 (0.42) | PTGS1GSTK1TGFBR1OPRD1OPRM1 | |
| SCHEMBL30679729 | 1.00 | PTGS1 (0.42) | PTGS1GSTK1TGFBR1OPRD1OPRM1 | |
| SCHEMBL29527284 | 0.97 | TGFBR1 (0.43) | PTGS1GSTK1TGFBR1OPRD1OPRM1 | |
| SCHEMBL29420016 | 0.97 | TGFBR1 (0.43) | PTGS1GSTK1TGFBR1OPRD1OPRM1 | |
| SCHEMBL29382390 | 0.97 | TGFBR1 (0.43) | PTGS1GSTK1TGFBR1OPRD1OPRM1 | |
| SCHEMBL29528046 | 0.97 | TGFBR1 (0.43) | PTGS1GSTK1TGFBR1OPRD1OPRM1 | |
| SCHEMBL29540545 | 0.97 | PTGS1 (0.43) | PTGS1GSTK1TGFBR1OPRD1OPRM1 | |
| SCHEMBL29528171 | 0.97 | TGFBR1 (0.43) | PTGS1GSTK1TGFBR1OPRD1OPRM1 | |
| SCHEMBL29867949 | 0.94 | PTGS1 (0.42) | PTGS1GSTK1TGFBR1OPRD1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331779-A1 | BISPECIFIC FUSION POLYPEPTIDE COMPOUND | SHAANXI MICOT TECHNOLOGY CO., LTD. (CN) | 2023-10-19 | — | — | US | claimed |
| EP-4212542-A1 | BISPECIFIC FUSION POLYPEPTIDE COMPOUND | Shaanxi Micot Technology Limited Company (CN) | 2023-07-19 | — | — | EP | claimed |
| CN-115087662-A | Bispecific fusion polypeptide compounds | 陕西麦科奥特科技有限公司 | 2022-09-20 | — | — | CN | claimed |
| WO-2022052471-A1 | BISPECIFIC FUSION POLYPEPTIDE COMPOUND | 陕西麦科奥特科技有限公司 | 2022-03-17 | — | — | WO | claimed |
| US-20230331779-A1 | BISPECIFIC FUSION POLYPEPTIDE COMPOUND | SHAANXI MICOT TECHNOLOGY CO., LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| CN-115087662-B | Bispecific fusion polypeptide compounds | 陕西麦科奥特科技有限公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-114786704-B | Active polypeptide compound | 陕西麦科奥特科技有限公司 | 2023-08-25 | — | — | CN | disclosed |
| EP-4212542-A1 | BISPECIFIC FUSION POLYPEPTIDE COMPOUND | Shaanxi Micot Technology Limited Company (CN) | 2023-07-19 | — | — | EP | disclosed |
| CN-115087662-A | Bispecific fusion polypeptide compounds | 陕西麦科奥特科技有限公司 | 2022-09-20 | — | — | CN | disclosed |
| EP-4041278-A1 | ACTIVE POLYPEPTIDE COMPOUND | Shaanxi Micot Technology Limited Company (CN) | 2022-08-17 | — | — | EP | disclosed |
| CN-114786704-A | Active polypeptide compounds | 陕西麦科奥特科技有限公司 | 2022-07-22 | — | — | CN | disclosed |
| WO-2022052471-A1 | BISPECIFIC FUSION POLYPEPTIDE COMPOUND | 陕西麦科奥特科技有限公司 | 2022-03-17 | — | — | WO | disclosed |
| US-20050187160-A1 | Monopegylated growth hormone proteins | BOLDER BIOTECHNOLOGY INC. (US) | 2005-08-25 | — | — | US | disclosed |
| CN-1210400-C | Methods for making proteins containing free cysteine residues | BOLDER BIOTECHNOLOGY INC (US) | 2005-07-13 | — | — | CN | disclosed |
| US-20050026834-A1 | Methods for making proteins containing free cysteine residues | BOLDER BIOTECHNOLOGY, INC. | 2005-02-03 | — | — | US | disclosed |
| EP-1200124-A4 | IMMUNOGLOBULIN FUSION PROTEINS | BOLDER BIOTECHNOLOGY INC (US) | 2004-09-29 | — | — | EP | disclosed |
| US-6753165-B1 | FOR RESIDUES THAT DO NOT FORM DISULFIDE BOND | BOLDER BIOTECHNOLOGY, INC. | 2004-06-22 | — | — | US | disclosed |
| CN-1355842-A | Methods for making proteins containing free cysteine residues | BOLDER BIOTECHNOLOGY INC (US) | 2002-06-26 | — | — | CN | disclosed |
| EP-1200124-A1 | IMMUNOGLOBULIN FUSION PROTEINS | Bolder Biotechnology, Inc. (US) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001003737-A1 | IMMUNOGLOBULIN FUSION PROTEINS | BOLDER BIOTECHNOLOGY INC. (US) | 2001-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331779-A1 | BISPECIFIC FUSION POLYPEPTIDE COMPOUND | CALCR, BID, CASR | PTGS1 3213/4885GSTK1 3947/4885TGFBR1 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.